NCT07652775 rTMS Combined With Aerobic Exercise for Older Adults With Mild Cognitive Impairment and Comorbid Depression
| NCT ID | NCT07652775 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cheng-Hsin General Hospital |
| Condition | Mild Cognitive Impairment (MCI) |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2026-03-03 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 45 participants in total. It began in 2026-03-03 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) and aerobic exercise on cognitive function and mental health in older adults with mild cognitive impairment (MCI) and comorbid depression. Forty-five participants will be randomly assigned to one of three groups: (1) rTMS alone, (2) rTMS combined with stationary cycling exercise, or (3) sham rTMS combined with stationary cycling exercise. Participants will receive 20 intervention sessions over a 5-week period (4 sessions per week). Outcomes, including cognitive function, depressive symptoms, sleep quality, life satisfaction, self-efficacy, and gait performance, will be assessed at baseline, immediately after completion of the 5-week intervention, and at a 1-month follow-up. The findings may contribute to the development of evidence-based, non-pharmacological interventions for improving cognitive and mental health outcomes in older adults with MCI and comorbid depression.
Eligibility Criteria
Inclusion Criteria: 1. Aged 65 to 90 years. 2. Diagnosed with mild cognitive impairment (MCI) according to established clinical criteria. 3. Presence of depressive symptoms as determined by clinical assessment and Beck Depression Inventory-II (BDI-II). 4. Able to communicate and follow study instructions. 5. Able to ambulate independently with or without an assistive device. 6. Able to provide written informed consent. Exclusion Criteria: 1. Diagnosis of dementia. 2. History of epilepsy or seizure disorder. 3. Presence of metallic implants, pacemakers, cochlear implants, or other contraindications to transcranial magnetic stimulation. 4. Major neurological disorders, including stroke, Parkinson's disease, traumatic brain injury, or other neurodegenerative diseases. 5. Severe psychiatric disorders other than depression. 6. Severe cardiovascular, musculoskeletal, or medical conditions that preclude participation in aerobic exercise. 7. Severe visual or hearing impairments that interfere with cognitive assessment. 8. Current participation in another intervention study.
Contact & Investigator
Kai-Chen Wang, MD
PRINCIPAL INVESTIGATOR
Cheng-Hsin General Hospital
Frequently Asked Questions
Who can join the NCT07652775 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, up to 90 Years, studying Mild Cognitive Impairment (MCI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07652775 currently recruiting?
Yes, NCT07652775 is actively recruiting participants. Contact the research team at aya45285@gmail.com for enrollment information.
Where is the NCT07652775 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT07652775 clinical trial?
NCT07652775 is sponsored by Cheng-Hsin General Hospital. The principal investigator is Kai-Chen Wang, MD at Cheng-Hsin General Hospital. The trial plans to enroll 45 participants.